UNSPSC 51343510: Tenofovir df

This classification denotes a reverse transcriptase inhibitor and purine antagonist with the molecular formula C19H30N5O10P.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OTT9J7900I, chemically known as bis(hydroxymethyl) (((r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1), but more generally known as tenofovir df, which bears US NIH Compound Identifier 6398764.

European Medicines Agency schedules tenofovir df or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04721MIG. Most nations, for tariff purposes, schedule tenofovir df under HS 29335995. SMILES: C[C@H](CN1CNC2C1NCNC2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51343510 Tenofovir df is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though the recent opportunities tagged to this code show significant misalignment with its nominal scope. The Seminole County, Florida IFB (IFB60459723LAS, due July 26, 2023) seeks naloxone and drug deactivation systems for community health initiatives—opioid-response supplies rather than the antiretroviral drug tenofovir. The City of Tampa's ITB for medical and first aid supplies (26P00145, due March 13, 2026) covers emergency response consumables for the Fire Department Rescue Division, including respiratory equipment, cardiac electrodes, and bandaging materials. The Texas HHS Commission RFI (HHS0017013, April 3, 2026) pursues direct-to-manufacturer prescription fulfillment strategies without specifying drug classes. Only the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) explicitly addresses generic multi-source pharmaceuticals and OTC products across state and local facilities, with pricing and product compliance the primary evaluation drivers. The code shows little relevant recent activity; issuing bodies include county health departments, municipal fire services, and state health agencies, but the opportunities do not reflect consistent procurement of tenofovir or similar antiretroviral agents.

Geographic activity appears concentrated in Florida, Texas, and Minnesota, with the MMCAP cooperative purchasing vehicle extending to Oregon. The Seminole County opportunity targets quarterly deliveries to a single community health building; the Tampa Fire Department procurement is city-wide; the Texas RFI addresses statewide pharmacy benefit programs; and MMCAP serves multi-state government and local facilities. No recent opportunities explicitly solicit tenofovir or similar antiretroviral drugs by name or NDC. The City of Tampa's medical and first aid supplies bid (estimated at $700,000.00) carries a Small Local Business Enterprise (SLBE) set-aside with a 5 percent bid discount not to exceed $10,000, reflecting local market designation. The MMCAP RFP requires cGMP and DSCSA compliance, $5 million commercial general liability coverage, and performance penalties for reporting or onboarding delays. Without opportunities directly targeting antiretroviral procurement under this code, activity signals are weak; prospective vendors should verify whether state and local health agencies are purchasing tenofovir through alternative UNSPSC codes or through cooperative purchasing arrangements not yet reflected in recent postings.